Stay updated with breaking news from Stephan Jackman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alzamend Neuro Inc ALZN received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for…
Alzamend Neuro Inc (NASDAQ: ALZN) received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for
Alzamend Neuro Inc (NASDAQ: ALZN) has received a "Study May Proceed" letter from the FDA for the initiation of study AL001-MDD01, a Phase 2A clinical study of AL001 for
By Dean Seal Alzamend Neuro has gotten the go-ahead from federal regulators to launch a clinical study of its treatment for major depressive disorder. The biopharmaceutical company said...